Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial
A substantial and unmet clinical need exists for pharmacological treatment of cannabis use disorders. Cannabidiol could offer a novel treatment, but it is unclear which doses might be efficacious or safe. In the first randomized clinical trial, cannabidiol 400 mg and 800 mg were safe and more efficacious than placebo at reducing cannabis use.

Related Post